[Lanreotide in the treatment of thyroid orbitopathy].
The aim of the present study was to evaluate the efficiency of somatostatin analogue--lanreotide in the treatment of Graves ophthalmopathy. We examined the group of 6 women with thyroid eye disease in class 2 and 3 according to NO SPECS classification. Ophthalmopathy index and clinical activity score were above 3. Lanreotide was given in a dose of 30 mg i.m. every 2 weeks over a period of 3 months. The therapeutic effect was evaluated twice: 2 weeks after the end of lanreotide treatment (initial assessment) and after 2 years (final assessment). On initial assessment a decrease in ophthalmopathy index more than 2 points in each eye was observed. On follow up after 2 years we did not observe the worsening of thyroid eye disease.


CONCLUSIONS
lanreotide is an effective drug in reduction of soft tissue inflammatory changes in patients with active Graves ophthalmopathy. Absence of recurrence of the disease in final assessment indicates the persistent effect of lanreotide treatment.
Pilarska
Krystyna
K
Klinika Endokrynologii, Nadciśnienia Tetniczego i Chorób Przemiany Materii Pomorskiej Akademii Medycznej w Szczecinie.
Kulig
Grzegorz
G
D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006111:Graves Disease / Q000188:drug therapy*; D006801:Humans; D008875:Middle Aged; D010456:Peptides, Cyclic / Q000008:administration & dosage / Q000627:therapeutic use*; D012720:Severity of Illness Index; D013004:Somatostatin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents; D010456:Peptides, Cyclic; C060347:lanreotide; D013004:Somatostatin